Medindia LOGIN REGISTER
Medindia
Advertisement

Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention

Thursday, June 12, 2008 General News
Advertisement
NOVATO, Calif., June 12 Raptor Pharmaceuticals Corp.(OTC Bulletin Board: RPTP), today announced that Ted Daley, President of BennuPharmaceuticals Inc., Raptor's clinical development subsidiary, will presentat the 2008 BIO International Convention to be held June 17-20, 2008 at theSan Diego Convention Center in San Diego, CA.
Advertisement

Mr. Daley's 15-minute corporate overview will take place on Wednesday,June 18, 2008 at 1:15p.m. (PT) in room 4 of the CNS/Neurology track.

For more information on this event please visit: http://www.bio2008.org .
Advertisement

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100%ownership of development stage biotechnology company Raptor PharmaceuticalInc. ("Raptor Inc."); and its 100% ownership of clinical-stage developmentcompany Bennu Pharmaceuticals Inc. ("Bennu"). Raptor Inc. bioengineers noveldrug candidates and drug-targeting platforms derived from the humanreceptor-associated protein ("RAP") and related proteins, while Bennu advancesclinical-stage product candidates towards marketing approval andcommercialization.

Raptor Inc.'s preclinical programs target cancer, neurodegenerativedisorders and infectious diseases. HepTide(TM) is designed to utilizeengineered RAP-based peptides conjugated to drugs to target their delivery tothe liver to potentially treat primary liver cancer and hepatitis. Inneurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) arecurrently undergoing evaluation at Stanford University in cell culture andpreclinical models for their ability to enhance the transport of moleculesfrom blood to the brain. In an effort to protect its novel approach, RaptorInc. currently has five patent applications in review in the U.S., andcountries in Europe and Asia, as well as two provisional patent applicationslicensed from Washington University. In addition, Raptor Inc. has recentlysubmitted two new provisional patent applications in the U.S., the first ofwhich covers a new family of RAP peptides, and the second application tofurther support and expand its coverage in specific disease indications.

Bennu executes the clinical development of product candidates developedinternally at Raptor Inc. and in-licensed candidates that are: 1) new chemicalentities in mid-to-late stage clinical development; 2) currently approveddrugs with potential efficacy in additional indications; and 3) treatmentsthat may be repurposed or reformulated as potentially more effective orconvenient treatments for their currently approved indications. Bennu'sinitial clinical programs include the treatment of aldehyde dehydrogenase("ALDH2") deficiency, nephropathic cystinosis and NASH.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is definedin the Private Securities Litigation Reform Act of 1995. These statementsrelate to future events or our future results of operation or future financialperformance, including, but not limited to the following statements: theCompany's ability to develop, obtain regulatory approval and commercialize itsclinical and preclinical product candidate programs. These statements are onlypredictions and involve known and unknown risks, uncertainties and otherfactors, which may cause our actual results to be materially different fromthese forward-looking statements. Factors which may significantly change orprevent our forward looking statements from fruition include that we may beunsuccessful in developing any products or acquiring products; that ourtechnology may not be validated as we progress further and our methods may notbe accepted by the scientific community; that we are unable to retain orattract key employees whose knowledge is essential to the development of ourproducts; that unforeseen scientific difficulties develop with our process;that our patents are not sufficien
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close